CSF1R and Miyoshi myopathy: Finally, our finding, in which blockade of CSF1R recovers the melphalan-induced cytotoxicity weakened by pre-ASCT M-MDSCs, allow us to take the next step in therapeutically targeting MDSCs in patients with MM undergoing ASCT.